At a glance
ClinicalIndex Comparison RecordPhase 2Active· 35 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Pembrolizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Bavituximab for Hepatocellular Carcinoma. Active but no longer recruiting, targeting 35 participants across 2 sites.
Detailed Summary
This is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC. Locally advanced or metastatic HCC is defined as disease that is not amenable to surgical and/or locoregional therapies. Subjects must not have received prior systemic therapy for advanced HCC in keeping with the first-line setting of this study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2ActiveOverdue
20192020202120222023202420252026
Enrollment StartApr 2018
First PostedMay 2018
Primary CompletionApr 2023
Study CompletionApr 2026
TodayJul 2026
First PostedMay 9, 2018
Enrollment StartApr 26, 2018
Primary CompletionApr 21, 2023
Study CompletionApr 1, 2026
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 8.1 years ago
Interventions
Pembrolizumabdrug
Pembroluzumab 200mg IV once every 3 weeks
Bavituximabdrug
Bavituximab 3mg/kg IV weekly